MBCproject_0095_T3_RNA
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- INTERFERON_GAMMA_RESPONSE+0.620
- ALLOGRAFT_REJECTION+0.540
- E2F_TARGETS+0.540
- MYC_TARGETS_V2+0.530
- G2M_CHECKPOINT+0.460
- MYC_TARGETS_V1+0.460
- INFLAMMATORY_RESPONSE+0.350
- IL6_JAK_STAT3_SIGNALING+0.340
- MITOTIC_SPINDLE+0.240
Top 10 suppressed
- TGF_BETA_SIGNALING-0.430
- ESTROGEN_RESPONSE_EARLY-0.420
- UV_RESPONSE_DN-0.400
- ANGIOGENESIS-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- FATTY_ACID_METABOLISM-0.370
- ANDROGEN_RESPONSE-0.320
- PROTEIN_SECRETION-0.290
- ADIPOGENESIS-0.280
- COAGULATION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613746 | — | D | 0.919 |
| 2 | MBCProject_5971_T1_RNA | — | D | 0.917 |
| 3 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.914 |
| 4 | TCGA-E2-A1LI-01A-12R-A157-07 | — | E | 0.904 |
| 5 | TCGA-OL-A5D7-01A-11R-A27Q-07 | — | E | 0.902 |
| 6 | TCGA-BH-A1FC-01A-11R-A13Q-07 | — | E | 0.894 |
| 7 | 20100125.TNBC | — | E | 0.892 |
| 8 | 20030081.TNBC | — | D | 0.888 |
| 9 | TCGA-AC-A6IW-01A-12R-A33J-07 | — | E | 0.886 |
| 10 | TCGA-90-A4EE-01A-11R-A24Z-07 | — | cohortSQ1 | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.620 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |